Rezolute Inc Ordinary Shares RZLT 深 沪
交易中 10-29 11:03:11 美东时间
9.44
-0.050
-0.53%
华盛通- 最 高9.79
- 今 开9.79
- 成交量 18.11万股
- 最 低 9.415
- 昨 收 9.49
- 总市值 8.21亿
- 52周最高 10.04
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.215
- 委 比 -68.33%
- 总股本 8699.60万
- 历史最高 21.11
- 量 比 0.49
- 振 幅 3.95%
- 历史最低 0.72
- 每 手 1
- 风险率 1.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rezolute, Inc. granted equity inducement awards to two new employees as of September 30, 2025. These awards, approved by the Compensation Committee, include options to purchase 125,000 shares of common stock with a $9.40 exercise price, vesting over four years. This move aims to incentive employee acceptance of employment with the company. Forward-looking statements are provided with standard disclaimers regarding risks and uncertainties.
10-09 20:05
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
10-07 01:35
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
美股大行评级 | 潜在涨幅302.68%！Maxim Group上调T Stamp目标价至12美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持T Stamp"买入"评级，目标价从8美元升至12美元；Maxim Group：维持Rezolute"买入"评级，目标价从15美元升至20美元
09-22 18:44
美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
09-19 09:18
BTIG Reiterates Buy on Rezolute, Maintains $17 Price Target
BTIG analyst Julian Harrison reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $17 price target.
09-18 17:40
Rezolute GAAP EPS of -$0.26 misses by $0.01
Rezolute press release (NASDAQ:RZLT): Q4 GAAP EPS of -$0.26 misses by $0.01. Cash, cash equivalents and investments in marketable securities were $167.9 million as of June 30, 2025, compared with $127...
09-18 16:48
Rezolute Q4 EPS $(0.26) Misses $(0.22) Estimate
Rezolute (NASDAQ:RZLT) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.22) by 18.18 percent. This is a 40.91 percent increase over losses of $(0.44) per share from the
09-18 04:08
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
Rezolute, Inc. reported financial results and business updates for the fiscal year ended June 30, 2025, highlighting progress in their Phase 3 trials for ersodetug, a treatment for hypoglycemia caused by hyperinsulinism. The company achieved enrollment in the sunRIZE trial for congenital hyperinsulinism and aligned with the FDA on a streamlined clinical path for tumor hyperinsulinism. Financially, the company held $167.9 million in cash and saw i...
09-17 20:05
HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $14 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $14 price target.
09-03 19:12
